# US 2021/0267937 A1 · Methods for the treatment of inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267937 A1
- Document ID: US20210267937A1
- Status: Published application
- Kind: A1
- Application number: 17/189,482
- Filed: 2021-03-02
- Published: 2021-09-02
- Earliest claimed: 2020-03-02
- Assignees: University of South Florida; SprainGo, LLC
- Applicants: University of South Florida; SprainGo, LLC
- Inventors: Bill J. Baker; Sofia Kokkaliari; James Leahy; Wayne Caleb Williams
- Web page: https://patentgrep.com/patent/US20210267937A1

## CPC

- A61K 31/366: having six-membered rings, e.g. delta-lactones
- C07D 311/78: Ring systems having three or more relevant rings
- A61K 36/15: Pinaceae (Pine family), e.g. pine or cedar
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 2236/00: Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K 2236/39: Complex extraction schemes, e.g. fractionation or repeated extraction steps
- A61K 2236/51: Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is directed to methods for the treatment of inflammation or pain, particularly methods using compositions containing a compound of formula (I).

## Claims

### Claim 1

A method for treating inflammation in a subject in need thereof comprising administering a composition comprising at least 1 wt. % based on the total weight of the composition of a compound of formula (I):
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inflammation is acute inflammation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inflammation is chronic inflammation.

### Claim 4 (depends on 1)

The method of claim 1, wherein the inflammation is associated with an inflammatory disorder.

### Claim 5 (depends on 1)

The method of claim 1, wherein the inflammation is selected from encephalitis, myelitis, meningitis, neuritis, dacryoadenitis, scleritis, episcleritis, keratitis, otitis, endocarditis, myocarditis, pericarditis, arteritis, phlebitis, capillaritis, sinusitis, rhinitis, pharyngitis, epiglottitis, laryngitis, tracheitis, bronchitis, pneumonitis, pleurisy, stomatitis, gingivitis, glossitis, tonsillitis, sialadenitis, parotitis, cheilitis, pulpitis, gnathitis, oesophagitis, gastritis, gastroenteritis, enteritis, colitis, pancolitis, appendicitis, cryptitis, hepatitis, cholecystitis, pancreatitis, dermatitis, mastitis, arthritis, myositis, synovitis, tenosynovitis, bursitis, nephritis, ureteritis, cystitis, urethritis, oophoritis, salpingitis, endometritis, myometritis, parametritis, cervicitis, vaginitis, vulvitis, orchitis, epididymitis, prostatitis, vasculitis, balanitis, posthitis, insulitis, hypophysitis, thyroiditis, parathyroiditis, adrenalitis, lymphangitis and lymphadenitis.

### Claim 6 (depends on 1)

The method of claim 1, wherein the inflammation is associated with arthritis.

### Claim 7 (depends on 6)

The method of claim 6, wherein the arthritis is selected from rheumatoid arthritis, spondyloarthopathies, gouty arthritis, systemic lupus erythematosus, osteoarthritis, and juvenile arthritis.

### Claim 8 (depends on 1)

The method of claim 1, wherein the inflammation is associated with asthma, bronchitis, menstrual cramps, tendinitis, bursitis, psoriasis, eczema, burns or dermatitis.

### Claim 9 (depends on 1)

The method of claim 1, wherein the inflammation is associated with a gastrointestinal condition.

### Claim 10 (depends on 9)

The method of claim 9, wherein the gastrointestinal condition is selected from inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome, and ulcerative colitis.

### Claim 11 (depends on 1)

The method of claim 1, wherein the inflammation is associated with vascular disease, migraine headaches, perarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, scleroderma, rheumatic fever, type I diabetes, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, hypersensitivity, conjunctivitis, gingivitis, swelling occurring after an injury, or myocardial ischemia.

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition further comprises an additional therapeutic.

### Claim 13 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is present in the composition in an amount of at least 5 wt. %, at least 10 wt. %, at least 20 wt. %, at least 30 wt. %, or more based upon the total weight of the composition.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 15

A method for the treatment of pain in a subject in need thereof comprising administering a composition comprising at least 1 wt. % based on the total weight of the composition of a compound of formula (I):
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the pain is selected from acute pain, chronic pain, nociceptive pain, neuropathic pain, cancer pain, and psychogenic pain.

### Claim 17 (depends on 15)

The method of claim 15, wherein the composition further comprises an additional therapeutic.

### Claim 18 (depends on 15)

The method of claim 15, wherein the compound of formula (I) is present in the composition in an amount of at least 5 wt. %, at least 10 wt. %, at least 20 wt. %, at least 30 wt. %, or more based upon the total weight of the composition.

### Claim 19 (depends on 15)

The method of claim 15, wherein the subject is a human.

### Claim 20

A method of isolating from pine rosin a compound of formula (I)
the method comprising:
(a) contacting the pine rosin with a solvent such that a portion of the compound of formula (I) is extracted into the solvent to provide a first extract;
(b) removing the solvent to provide a first concentrate;
(c) subjecting the first concentrate to a separation technique that provides a plurality of fractions;
(d) testing each fraction within the plurality fractions for inhibitory activity against COX-2 or TNF-α;
(e) removing the solvent from the fraction within the plurality of fractions with the highest inhibitory activity against COX-2 or TNF-α to provide a second concentrate; and
(f) repeating steps (c) to (e) until the concentrate contains the compound of formula (I) in a purity of greater than 90%.
